Study to Evaluate the Efficacy of Zanzalintinib in the Treatment of Relapsed or Metastatic Adenoid Cystic Carcinomas of the Head and Neck

NCT07682675 | Not Yet Recruiting Phase 2

• 2 other identifiers: UC-HNG-26072026-527475-28-00
• Study Type: interventional
• Target: 51
• Locations: 1 country
• Sites: 2

Brief Summary

Adenoid cystic carcinomas are rare cancers of the salivary glands. These cancers are treated with curative surgery, often followed by radiation therapy. Despite this aggressive treatment, approximately 50% of patients will develop a recurrence or metastatic disease (spread of the disease to another part of the body). Treatment of this progressive disease with chemotherapy or targeted therapy has not demonstrated significant efficacy so far, and there are currently no management recommendations from health authorities. The emergence of new drugs offers hope for patients. Zanzalintinib, thanks to its specific mechanisms of action, could be an effective treatment for patients whose disease has progressed.

Conditions

Adenoid Cystic Carcinoma of the Salivary Gland; Recurrence; Metastatic Disease

Outcome Measures

Primary Outcomes (1)

• Efficacy of zanzalintinib in patients with recurrent and/or metastatic ACC patients in terms of Objective Response Rate (ORR) at 12 weeks

  Objective response rate (ORR), defined as the rate of patients with Complete Response or Partial Response (according to RECIST 1.1) as determined by investigator

  From baseline to week12 of treatment

Study Arms (1)

Experimental arm

EXPERIMENTAL

Drug: Zanzalintinib

Interventions

Zanzalintinib DRUG

per os 60mg daily

Experimental arm

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patient must have signed a written informed consent form prior to any trial specific procedures
• Patient ≥18 years of age on day of signing informed consent
• Adenoid Cystic Carcinoma (histologically proven) originating from the head and neck region in relapse and/or metastatic, not suitable for local therapy
• Subjects must have at least 1 lesion measurable per RECIST v1.1 Criteria, with MRI or CT-scan
• Patients with significant disease progression diagnosed within 3 months prior to enrollment, defined by radiological progression according to RECIST 1.1 determined by the comparison of 2 CT scans or 2 MRIs separated by a maximum of 6 months.
• Performance Status 0-1
• Recovery to baseline or ≤ Grade 1 severity (National Cancer Institute - common terminology criteria for adverse events version 6.0 \[NCI-CTCAE v6.0\]) from adverse events (AEs), including immune-related adverse events (irAEs), related to any prior treatments, unless AE(s) are clinically nonsignificant and/or stable on supportive therapy (eg, physiological replacement of corticosteroid). Low-grade or controlled toxicities such as alopecia, ≤ Grade 2 hypomagnesemia, ≤ Grade 2 neuropathy are permitted).
• Adequate bone marrow function within 14 days before first dose of study treatment (absolute neutrophil count \> 1,500 cells/mm3, platelets \> 100,000 cells/mm3, Hb \> 9g/dl, INR) ≤ 1.5 and activated partial thromboplastin time (aPTT) ≤ 1.2 x upper limit of normal (ULN).
• Adequate liver function within 14 days before first dose of study treatment (total bilirubin ≤ 1.5 x UNL (for subjects with Gilbert's disease ≤ 3 x ULN), AST, ALT and ALP ≤ 3 x UNL or \< 5 x UNL in case of hepatic metastasis).
• Serum creatinine ≤ 1.5 x ULN or calculated creatinine clearance ≥ 40 mL/min (≥ 0.67 mL/sec) using the Cockcroft Gault equation.
• Urine protein-to-creatinine ratio (UPCR) ≤ 1 mg/mg (≤ 113.2 mg/mmol) creatinine
• Patients must be willing and able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures
• Patients must be affiliated to a Social Security System
• Women of childbearing potential must have a negative serum β-HCG pregnancy test within 7 days and/or negative urine pregnancy test within 48 hours prior to the administration of the first study treatment. Female subjects are considered to be of childbearing potential unless one of the following criteria is met: permanent sterilization (hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) or documented postmenopausal status (defined as 12 months of amenorrhea in a woman \> 45 years-of-age in the absence of other biological or physiological causes. In addition, females \< 55 years-of-age must have a serum follicle stimulating hormone \[FSH\] level \> 40 mIU/mL to confirm menopause). Note: Documentation may include review of medical records, medical examination, or medical history interview by study site staff.
• Sexually active fertile subjects and their partners must agree to use highly effective method of contraception during the course of the study and through 186 days after the last dose of zanzalintinib for women of childbearing potential (WOCBP) or through 96 days after the last dose of zanzalintinib for men (whichever is later). An additional contraceptive method, such as a barrier method (eg, condom), is required. In addition, men must agree not to donate sperm and women must agree not to donate eggs (ova, oocyte) for the purpose of reproduction during these same periods.

You may not qualify if:

• Prior treatment with zanzalintinib or with another inhibitor of VEGFR
• Receipt of any type of small molecule kinase inhibitor (including investigational kinase inhibitor) within 2 weeks before first dose of study treatment.
• Receipt of any type of cytotoxic, biologic or other systemic anticancer therapy (including investigational) within 4 weeks before first dose of study treatment.
• Radiation therapy for bone metastasis within 2 weeks, any other radiation therapy within 4 weeks before first dose of study treatment. Systemic treatment with radionuclides within 6 weeks before first dose of study treatment. Subjects with clinically relevant ongoing complications from prior radiation therapy are not eligible.
• Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 4 weeks before first dose of study treatment. Note: Eligible subjects must be neurologically asymptomatic and without corticosteroid treatment at the time of enrollment. Note: Base of skull lesions without definitive evidence of dural or brain parenchymal involvement are allowed.
• Concomitant anticoagulation with oral anticoagulants (eg, warfarin, direct thrombin inhibitors ) and platelet inhibitors (eg, clopidogrel).
• Allowed anticoagulants are the following:
• Prophylactic use of low-dose aspirin for cardio-protection (per local applicable guidelines) and low-dose low molecular weight heparins (LMWH).
• Therapeutic doses of LMWH or anticoagulation with direct factor Xa inhibitors rivaroxaban, edoxaban, or apixaban in subjects without known brain metastases who are on a stable dose of the anticoagulant for at least 1 week before first dose of study treatment without clinically significant hemorrhagic complications from the anticoagulation regimen.
• Note: Subjects must have discontinued oral anticoagulants within 3 days or 5 half-lives prior to first dose of study treatment, whichever is longer.
• Any complementary medications (eg, herbal supplements or traditional Chinese medicines) to treat the disease under study within 2 weeks before first dose of study treatment.
• The subject has uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions:
• a) Unstable of deteriorating cardiovascular disorders: i. Congestive heart failure New York Heart Association Class 3 or 4, class 2 or higher, unstable angina pectoris, new-onset angina, serious cardiac arrhythmias (eg, ventricular flutter, ventricular fibrillation, Torsades de pointes).
• ii. Uncontrolled hypertension defined as sustained blood pressure (BP) \> 140 mm Hg systolic or \> 90 mm Hg diastolic despite optimal antihypertensive treatment.
• iii. Stroke (including transient ischemic attack \[TIA\]), myocardial infarction, or other clinically significant arterial thrombotic and/or ischemic event within 6 months before first dose of study treatment.

Sponsors & Collaborators

• UNICANCER: lead

Study Sites (2)

Oncopole Claudius Regaud

Toulouse, 31052, France

Location

Gustave Roussy

Villejuif, 94800, France

Location

MeSH Terms

Conditions

Recurrence; Neoplasm Metastasis

Condition Hierarchy (Ancestors)

Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Neoplastic Processes; Neoplasms

Study Officials

• Caroline EVEN, MD

  Gustave Roussy, Département de cancérologie cervico-faciale

  PRINCIPAL INVESTIGATOR

• Victor SARRADIN, MD

  Oncopole Claudius Regaud, Département d'oncologie médicale

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Michaël CHEVROT

CONTACT

+33171936161; m-chevrot@unicancer.fr

Laure Monard

CONTACT

l-monard@unicancer.fr

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 26, 2026
• First Posted: July 6, 2026
• Study Start (Estimated): October 1, 2026
• Primary Completion (Estimated): April 1, 2029
• Study Completion (Estimated): April 1, 2032
• Last Updated: July 6, 2026

Record last verified: 2026-06

Locations

FR (2)